Nokea
GLP-1 agonists:
- A. Directly bind to a receptor in the pancreatic beta cell
- B. Have been approved for monotherapy
- C. Speed gastric emptying to decrease appetite
- D. Can be given orally once daily
Correct Answer: A
Rationale: GLP-1 agonists bind beta-cell receptors to enhance insulin release; they're not monotherapy-approved or oral .
You may also like to solve these questions
Which route of drug administration is most likely to lead to first pass effect?
- A. Sublingual
- B. Oral
- C. Intravenous
- D. Intramuscular
Correct Answer: B
Rationale: Oral administration subjects drugs to the first-pass effect, where they are metabolized by the liver via the portal vein before reaching systemic circulation, reducing bioavailability.
Incorporating information technology (IT) into a patient encounter takes skill and tact. During the encounter, the provider can make the patient more comfortable with the IT the provider is using by:
- A. Turning the screen around so the patient can see material being recorded
- B. Not placing the computer screen between the provider and the patient
- C. Both 1 and 2
- D. Neither 1 nor 2
Correct Answer: C
Rationale: Both actions reduce barriers and enhance patient comfort with IT use.
Which statement is correct regarding glucagon:
- A. Causes hypoglicemia
- B. Haven't affect glucose level in the blood
- C. Has a positive inotroic effect
Correct Answer: C
Rationale: Glucagon has a positive inotropic effect on the heart, increasing contractility, in addition to raising blood glucose levels.
If an agonist can produce submaximal effects and has moderate efficacy it's called:
- A. Partial agonist
- B. Antagonist
- C. Agonist-antagonist
- D. Full agonist
Correct Answer: A
Rationale: A partial agonist produces a submaximal effect even at full receptor occupancy.
Most common indication for therapeutic monitoring of plasma levels of a drug is
- A. Hit & run drugs
- B. Drugs with irreversible action
- C. Narrow therapeutic range
- D. Failure of response
Correct Answer: C
Rationale: Drugs with a narrow therapeutic range (e.g., digoxin) require monitoring to avoid toxicity.